This article in The Wall Street Journal follows the path of medical-robotics maker Myomo (ticker: MYO), which completed its Reg A+ offering in 2017. While the capital needs differed from a typical IPO company, the story explains how the process looks strikingly similar to the traditional route. Regulatory filings were designed to mimic the traditional format and investment banks marketed most of the deal to institutions and high net worth individuals.